Unicycive Therapeutics Inc., a biotechnology company, develops therapies for kidney diseases in the U.S. It is developing Renazorb, a treatment for hyperphosphatemia in patients with chronic kidney disease, and UNI 494, a treatment for Acute Kidney Injury. The company was incorporated in 2016 and is headquartered in Los Altos, CA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$7.77 | A | |
$22.48 | A | |
$40.37 | A |